ARROWHEAD PHARMACEUTICALS ($ARWR) posted quarterly earnings results on Monday, May 12th. The company reported earnings of $2.75 per share, beating estimates of -$0.20 by $2.95. The company also reported revenue of $542,710,000, beating estimates of $30,504,375 by $512,205,625.
You can see Quiver Quantitative's $ARWR stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ARROWHEAD PHARMACEUTICALS Insider Trading Activity
ARROWHEAD PHARMACEUTICALS insiders have traded $ARWR stock on the open market 29 times in the past 6 months. Of those trades, 0 have been purchases and 29 have been sales.
Here’s a breakdown of recent trading of $ARWR stock by insiders over the last 6 months:
- CHRISTOPHER RICHARD ANZALONE (Chief Executive Officer) has made 0 purchases and 13 sales selling 543,342 shares for an estimated $8,615,696.
- KENNETH ALLEN MYSZKOWSKI (Chief Financial Officer) has made 0 purchases and 4 sales selling 45,167 shares for an estimated $893,095.
- PATRICK O'BRIEN (COO and General Counsel) has made 0 purchases and 3 sales selling 37,184 shares for an estimated $736,058.
- JAMES C HAMILTON (Chief Discovery/Trans Medicine) has made 0 purchases and 2 sales selling 32,729 shares for an estimated $648,824.
- VICTORIA VAKIENER sold 8,994 shares for an estimated $197,058
- WILLIAM D. WADDILL has made 0 purchases and 2 sales selling 7,495 shares for an estimated $164,665.
- DOUGLAS B GIVEN has made 0 purchases and 2 sales selling 5,547 shares for an estimated $121,555.
- ADEOYE Y OLUKOTUN has made 0 purchases and 2 sales selling 3,809 shares for an estimated $77,139.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ARROWHEAD PHARMACEUTICALS Hedge Fund Activity
We have seen 125 institutional investors add shares of ARROWHEAD PHARMACEUTICALS stock to their portfolio, and 145 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 3,748,154 shares (+23.2%) to their portfolio in Q1 2025, for an estimated $47,751,481
- AVORO CAPITAL ADVISORS LLC added 2,222,223 shares (+25.0%) to their portfolio in Q4 2024, for an estimated $41,777,792
- FMR LLC removed 1,786,001 shares (-35.0%) from their portfolio in Q1 2025, for an estimated $22,753,652
- JPMORGAN CHASE & CO removed 1,532,755 shares (-75.9%) from their portfolio in Q1 2025, for an estimated $19,527,298
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,067,277 shares (-29.9%) from their portfolio in Q4 2024, for an estimated $20,064,807
- VANGUARD GROUP INC added 1,018,273 shares (+8.4%) to their portfolio in Q1 2025, for an estimated $12,972,798
- UBS GROUP AG added 863,818 shares (+195.7%) to their portfolio in Q4 2024, for an estimated $16,239,778
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ARROWHEAD PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $ARWR in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 11/27/2024
- Chardan Capital issued a "Buy" rating on 11/27/2024
To track analyst ratings and price targets for ARROWHEAD PHARMACEUTICALS, check out Quiver Quantitative's $ARWR forecast page.
ARROWHEAD PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $ARWR recently. We have seen 2 analysts offer price targets for $ARWR in the last 6 months, with a median target of $26.985.
Here are some recent targets:
- William Pickering from Bernstein set a target price of $24.0 on 11/29/2024
- Keay Nakae from Loop Capital Markets set a target price of $29.97 on 11/27/2024
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
